1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Growth Disorders – Pipeline Review, H1 2013

Growth Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 61 pages

Growth Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Growth Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Growth Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Disorders. Growth Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Growth Disorders.
- A review of the Growth Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Growth Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Growth Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Growth Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Growth Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth Disorders Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Growth Disorders 8
Growth Disorders Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Growth Disorders Therapeutics - Products under Development by Companies 16
Companies Involved in Growth Disorders Therapeutics Development 17
Novo Nordisk A/S 17
Zosano Pharma, Inc. 18
PROLOR Biotech, Inc. 19
Biovitrum AB 20
JCR Pharmaceuticals Co., Ltd. 21
Asterion Ltd 22
Physica Pharma 23
GeneScience Pharmaceuticals Co., Ltd. 24
Phage Biotechnology Corporation 25
iBio, Inc. 26
USV Limited. 27
Growth Disorders - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
PHY-202 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
MOD-4023 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
somatropin - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
somatropin - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
bucelipase alfa - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
somatropin - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
somatropin Long-Acting - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
somatropin - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Growth Factors - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Human Growth Hormone ZP Patch - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
xl-020 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Growth Hormone Agonists - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Growth Disorders Therapeutics - Drug Profile Updates 50
Growth Disorders Therapeutics - Discontinued Products 54
Growth Disorders Therapeutics - Dormant Products 55
Growth Disorders - Product Development Milestones 56
Featured News and Press Releases 56
Sep 26, 2012: BioMarin Pharma Announces Phase I Results For BMN-111 For Achondroplasia 56
Sep 10, 2012: Ipsen Pharma Maintains Increlex Supply In US 56
Feb 16, 2012: BioMarin Initiates Phase I Trial For BMN-111 For Treatment Of Achondroplasia 56
Jan 03, 2012: BioMarin To Initiate Phase I Trial In BMN-111 For Treatment Of Achondroplasia 57
Nov 25, 2011: Hanmi Pharma Files With EMA For Orphan Drug Designation Of LAPS-rhGH 57
Nov 11, 2011: Hanmi Pharma To Maximize Commercial Opportunities Of LAPS-hGH Through EMA's Orphan Drug Designation And Pediatric Investigation Plan 57
Oct 27, 2011: Hanmi Pharma To Begin Phase II Study Of LAPS-hGH In European Territories 58
Oct 24, 2011: HanAll BioPharma Initiates Phase I Trial Of Vitatropin 58
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency 58
Aug 02, 2011: Swedish Orphan Biovitrum Announces First Patient Enrollment In Kiobrina Phase III Study 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61



List of Tables

Number of Products Under Development for Growth Disorders, H1 2013 8
Products under Development for Growth Disorders - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Comparative Analysis by Late Stage Development, H1 2013 12
Comparative Analysis by Mid Clinical Stage Development, H1 2013 13
Comparative Analysis by Early Clinical Stage Development, H1 2013 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Novo Nordisk A/S, H1 2013 17
Zosano Pharma, Inc., H1 2013 18
PROLOR Biotech, Inc., H1 2013 19
Biovitrum AB, H1 2013 20
JCR Pharmaceuticals Co., Ltd., H1 2013 21
Asterion Ltd, H1 2013 22
Physica Pharma, H1 2013 23
GeneScience Pharmaceuticals Co., Ltd., H1 2013 24
Phage Biotechnology Corporation, H1 2013 25
iBio, Inc., H1 2013 26
USV Limited., H1 2013 27
Assessment by Monotherapy Products, H1 2013 28
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Stage and Molecule Type, H1 2013 32
Growth Disorders Therapeutics - Drug Profile Updates 50
Growth Disorders Therapeutics - Discontinued Products 54
Growth Disorders Therapeutics - Dormant Products 55



List of Figures

Number of Products under Development for Growth Disorders, H1 2013 8
Products under Development for Growth Disorders - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 12
Mid Clinical Stage Products, H1 2013 13
Early Clinical Stage Products, H1 2013 14
Discovery and Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 28
Assessment by Route of Administration, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Molecule Type, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the Netherlands

  • December 2016
    18 pages
  • Therapy  

  • Netherlands  

    Canada  

View report >

Therapy Market and Blood Disease Statistics

  • December 2016
    8 pages
  • Therapy  

    Blood Disease  

View report >

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.